Renal cell carcinoma: Translational aspects of metabolism and therapeutic consequences

Kidney International

Volumn 84, Issue 4, 2013, Pages 667-681

  Yang, Oscar C Y ^a   Maxwell, Patrick H ^b   Pollard, Patrick J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cell signaling; metabolism; molecular genetics; mouse models; renal carcinoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; AZD 8055; BEVACIZUMAB; C MET MONOCLONAL ANTIBODY; CARBOPLATIN; CELL PROTEIN; EVEROLIMUS; FORETINIB; FUMARATE HYDRATASE; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR; IMATINIB; IRON SULFUR CLUSTER ASSEMBLY PROTEIN 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOCHONDRIAL DNA; PAZOPANIB; PLACEBO; PLATINUM SALT DERIVATIVE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RILOTUMUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ALLELE; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BIRT HOGG DUBE SYNDROME; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CHROMOPHOBE RENAL CELL CARCINOMA; COLLECTING DUCT RENAL CELL CARCINOMA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; FAMILY HISTORY; FLCN GENE; GAIN OF FUNCTION MUTATION; GENE; GENE CONTROL; GENETIC COUNSELING; GENETIC TRANSCRIPTION; HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HEREDITARY TYPE 1 PAPILLARY RENAL CELL CARCINOMA; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LOSS OF FUNCTION MUTATION; MEDULLARY RENAL CELL CARCINOMA; METABOLISM; MONOTHERAPY; MUCINOUS TUBULAR AND SPINDLE CELL CARCINOMA; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PAPILLARY RENAL CELL CARCINOMA; PENETRANCE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL CANCER METABOLISM; RENAL ONCOCYTOMA; REVIEW; RISK ASSESSMENT; RNA TRANSLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

ANIMALS; ANOXIA; ANTIOXIDANTS; CARCINOMA, RENAL CELL; CITRIC ACID CYCLE; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; EARLY DETECTION OF CANCER; HUMANS; KIDNEY NEOPLASMS; MICE; MITOCHONDRIA; SIGNAL TRANSDUCTION;

EID: 84885306769     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.245     Document Type: Review

References (234)

1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245-257.
2. Linehan WM, Bratslavsky G, Pinto PA et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 2010; 61: 329-343.
3. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 2763-2771.
4. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
5. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol 2007; 2: 145-173.
6. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
7. Woodward ER, Clifford SC, Astuti D et al. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 2000; 37: 348-353.
8. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
9. Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
10. Ivan M, Kondo K, Yang H et al. HIFa targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468.
11. Epstein ACR, Gleadle JM, McNeill LA et al. C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
12. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337-1340.
13. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
14. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009; 19: 12-16.
15. Simon MC. Coming up for air: HIF-1 and mitochondrial oxygen consumption. Cell Metab 2006; 3: 150-151.
16. Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol 2011; 76: 347-353.
17. Papandreou I, Cairns RA, Fontana L et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187-197.
18. Huang X, Ding L, Bennewith KL et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35: 856-867.
19. Chan SY, Zhang YY, Hemann C et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009; 10: 273-284.
20. Ye H, Rouault TA. Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease. Biochemistry 2010; 49: 4945-4956.
21. Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet 2008; 24: 398-407.
22. Kucejova B, Sunny NE, Nguyen AD et al. Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene 2011; 30: 2147-2160.
23. Favaro E, Ramachandran A, McCormick R et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010; 5: e10345.
24. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012; 491: 364-373.
25. Burnichon N, Briere JJ, Libe R et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010; 19: 3011-3020.
26. Astuti D, Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54.
27. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26: 268-270.
28. Baysal BE, Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851.
29. Ricketts CJ, Shuch B, Vocke CD et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012; 188: 2063-2071.
30. Bardella C, El-Bahrawy M, Frizzell N et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 2011; 225: 4-11.
31. Hao HX, Khalimonchuk O, Schraders M et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009; 325: 1139-1142.
32. Kim SS, Choi YD, Shim MK et al. Microscopic and nuclear morphometric findings of chromophobe renal cell carcinoma, renal oncocytoma, and tumor with overlapping histology. Ann Diagn Pathol 2012; 16: 429-435.
33. Barbosa IA, Machado NG, Skildum AJ et al. Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies. Biochim Biophys Acta 2012; 1826: 238-254.
34. Barletta JA, Hornick JL. Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications. Adv Anat Pathol 2012; 19: 193-203.
35. Selak MA, Armour SM, MacKenzie ED et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77-85.
36. Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005; 8: 155-167.
37. Rose NR, McDonough MA, King ONF et al. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 2011; 40: 4364-4397.
38. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008; 4: 152-156.
39. Cervera AM, Bayley JP, Devilee P et al. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer 2009; 8: 89.
40. Smith EH, Janknecht R, Maher LJ 3rd. Succinate inhibition of alphaketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 2007; 16: 3136-3148.
41. MacKenzie ED, Selak MA, Tennant DA et al. Cell-permeating alphaketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 2007; 27: 3282-3289.
42. He WH, Miao FJP, Lin DCH et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004; 429: 188-193.
43. Pluznick JL, Caplan MJ. Novel sensory signaling systems in the kidney. Curr Opin Nephrol Hypertens 2012; 21: 404-409.
44. Ariza AC, Deen PM, Robben JH. The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions. Front Endocrinol (Lausanne) 2012; 3: 22.
45. Yankovskaya V, Horsefield R, Tornroth S et al. Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 2003; 299: 700-704.
46. Slane BG, Aykin-Burns N, Smith BJ et al. Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res 2006; 66: 7615-7620.
47. Raha S, McEachern GE, Myint AT et al. Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase. Free Radic Biol Med 2000; 29: 170-180.
48. Guzy RD, Sharma B, Bell E et al. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 2008; 28: 718-731.
49. Ishii T, Yasuda K, Akatsuka A et al. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res 2005; 65: 203-209.
50. Selak MA, Duran RV, Gottlieb E. Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells. Biochim Biophys Acta 2006; 1757: 567-572.
51. Coppin C, Kollmannsberger C, Le L et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011; 108: 1556-1563.
52. Santos N, Wenger JB, Havre P et al. Combination therapy for renal cell cancer: what are possible options? Oncology 2011; 81: 220-229.
53. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
54. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
55. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
56. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-1939.
57. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428.
58. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150.
59. Ogunshola OO, Antic A, Donoghue MJ et al. Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem 2002; 277: 11410-11415.
60. Oladipupo S, Hu S, Kovalski J et al. VEGF is essential for hypoxiainducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc Natl Acad Sci USA 2011; 108: 13264-13269.
61. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
62. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
63. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
64. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-318.
65. Liu P, Cheng H, Roberts TM et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
66. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278-2287.
67. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
68. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122: 3589-3594.
69. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
70. DeBerardinis RJ, Lum JJ, Hatzivassiliou G et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
71. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
72. Pufall MA, Graves BJ. Autoinhibitory domains: modular effectors of cellular regulation. Annu Rev Cell Dev Biol 2002; 18: 421-462.
73. Otto T, Eimer C, Gerullis H. Temsirolimus in renal cell carcinoma. Transplant Proc 2008; 40: S36-S39.
74. Tsukamoto T, Shinohara N, Tsuchiya N et al. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011; 41: 17-24.
75. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591.
76. Fisher R, Larkin J, Swanton C. Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol 2012; 2: 49.
77. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010; 103: 1139-1143.
78. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
79. Merlo LM, Pepper JW, Reid BJ et al. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6: 924-935.
80. Xu X, Hou Y, Yin X et al. Single-cell exome sequencing reveals singlenucleotide mutation characteristics of a kidney tumor. Cell 2012; 148: 886-895.
81. Yap TA, Gerlinger M, Futreal PA et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps110.
82. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7: 277-285.
83. Lohela M, Bry M, Tammela T et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-165.
84. Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 2007; 29: 1159-1168.
85. Nepal M, Gong YD, Park YR et al. An activator of PHD2, KRH102140, decreases angiogenesis via inhibition of HIF-1alpha. Cell Biochem Funct 2011; 29: 126-134.
86. Jones DT, Harris AL. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 2006; 5: 2193-2202.
87. Cha TL, Chuang MJ, Wu ST et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 2009; 15: 840-850.
88. Audenet F, Yates DR, Cancel-Tassin G et al. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 2012; 109: 1864-1870.
89. Willems L, Chapuis N, Puissant A et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012; 26: 1195-1202.
90. Chresta CM, Davies BR, Hickson I et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288-298.
91. Sukov WR, Lohse CM, Leibovich BC et al. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol 2012; 187: 54-59.
92. Yu W, Zhang W, Jiang Y et al. Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information. Acta Histochem 2013; 115: 452-459.
93. Reuter VE, Tickoo SK. Differential diagnosis of renal tumours with clear cell histology. Pathology 2010; 42: 374-383.
94. Barrisford GW, Singer EA, Rosner IL et al. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol 2011; 2011: 658767.
95. Gherardi E, Birchmeier W, Birchmeier C et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
96. Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
97. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008; 18: 87-96.
98. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009; 19: 542-551.
99. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-848.
100. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009; 9: 785-793.
101. Herts BR, Coll DM, Novick AC et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol 2002; 178: 367-372.
102. Morris MR, Gentle D, Abdulrahman M et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 2005; 65: 4598-4606.
103. Morris MR, Maher ER. Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med 2010; 2: 59.
104. Kiuru M, Launonen V, Hietala M et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 2001; 159: 825-829.
105. Launonen V, Vierimaa O, Kiuru M et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 2001; 98: 3387-3392.
106. Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 2008; 9: 20.
107. Grubb RL 3rd, Franks ME, Toro J et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007; 177: 2074-2079; discussion 2079-2080.
108. Keegan KA, Schupp CW, Chamie K et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012; 188: 391-397.
109. Wei MH, Toure O, Glenn GM et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006; 43: 18-27.
110. Merino MJ, Torres-Cabala C, Pinto P et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007; 31: 1578-1585.
111. Sanz-Ortega J, Vocke C, Stratton P et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol 2013; 37: 74-80.
112. Tomlinson IP, Alam NA, Rowan AJ et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406-410.
113. Picaud S, Kavanagh KL, Yue WW et al. Structural basis of fumarate hydratase deficiency. J Inherit Metab Dis 2011; 34: 671-676.
114. Weaver TM, Levitt DG, Donnelly MI et al. The multisubunit active site of fumarase C from Escherichia coli. Nat Struct Biol 1995; 2: 654-662.
115. Salway JG. Metabolism at a Glance. Blackwell: West Sussex, UK, 1999.
116. Craig I, Tolley E, Bobrow M. Mitochondrial and cytoplasmic forms of fumarate hydratase assigned to chromosome 1. Cytogenet Cell Genet 1976; 16: 118-121.
117. Shambaugh GE 3rd. Urea biosynthesis I. The urea cycle and relationships to the citric acid cycle. Am J Clin Nutr 1977; 30: 2083-2087.
118. Stepinski J, Bizon D, Piec G et al. The purine nucleotide cycle activity in renal cortex and medulla. Am J Kidney Dis 1989; 14: 307-309.
119. Yogev O, Yogev O, Singer E et al. Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol 2010; 8: e1000328.
120. Lu H, Dalgard CL, Mohyeldin A et al. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005; 280: 41928-41939.
121. Hewitson KS, Lienard BM, McDonough MA et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 2007; 282: 3293-3301.
122. Adam J, Hatipoglu E, O'Flaherty L et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011; 20: 524-537.
123. Frizzell N, Rajesh M, Jepson MJ et al. Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin. J Biol Chem 2009; 284: 25772-25781.
124. Nagai R, Brock JW, Blatnik M et al. Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J Biol Chem 2007; 282: 34219-34228.
125. Thomas SA, Storey KB, Baynes JW et al. Tissue distribution of S-(2-succino)cysteine (2SC), a biomarker of mitochondrial stress in obesity and diabetes. Obesity (Silver Spring) 2012; 20: 263-269.
126. Frizzell N, Thomas SA, Carson JA et al. Mitochondrial stress causes increased succination of proteins in adipocytes in response to glucotoxicity. Biochem J 2012; 445: 247-254.
127. Frizzell N, Lima M, Baynes JW. Succination of proteins in diabetes. Free Radic Res 2011; 45: 101-109.
128. Ternette N, Yang M, Laroyia M et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep 2013; 3: 689-700.
129. Ooi A, Wong JC, Petillo D et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011; 20: 511-523.
130. McMahon M, Lamont DJ, Beattie KA et al. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci USA 2010; 107: 18838-18843.
131. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009; 284: 13291-13295.
132. Sun Z, Zhang S, Chan JY et al. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol 2007; 27: 6334-6349.
133. Yamamoto T, Suzuki T, Kobayashi A et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008; 28: 2758-2770.
134. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012; 12: 564-571.
135. Hayes JD, Ashford ML. Nrf2 orchestrates fuel partitioning for cell proliferation. Cell Metab 2012; 16: 139-141.
136. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003; 43: 233-260.
137. Kinch L, Grishin NV, Brugarolas J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 2011; 20: 418-420.
138. Ooi A, Dykema K, Ansari A et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 2013; 73: 2044-2051.
139. Copple IM. The Keap1-Nrf2 cell defense pathway-a promising therapeutic target? Adv Pharmacol 2012; 63: 43-79.
140. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011; 16: 123-140.
141. Hayes JD, McMahon M, Chowdhry S et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010; 13: 1713-1748.
142. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34: 176-188.
143. DeNicola GM, Karreth FA, Humpton TJ et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-109.
144. Homma S, Ishii Y, Morishima Y et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009; 15: 3423-3432.
145. Mitsuishi Y, Taguchi K, Kawatani Y et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012; 22: 66-79.
146. Pollard PJ, Spencer-Dene B, Shukla D et al. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 2007; 11: 311-319.
147. Yang Y, Valera VA, Padilla-Nash HM et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010; 196: 45-55.
148. Burgess TL, Sun J, Meyer S et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010; 9: 400-409.
149. Jin H, Yang R, Zheng Z et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 4360-4368.
150. Qian F, Engst S, Yamaguchi K et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009; 69: 8009-8016.
151. Albiges L, Molinie V, Escudier B. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target? Oncologist 2012; 17: 1051-1062.
152. Gordon MS, Sweeney CS, Mendelson DS et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010; 16: 699-710.
153. Munshi N, Jeay S, Li Y et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9: 1544-1553.
154. Choueiri TK, Vaishampayan U, Rosenberg JE et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31: 181-186.
155. Ravaud A, Barrios C, Anak Ñ et al. Genitourinary tumors, non-prostate. Ann Oncol 2012; 23: ix258-ix293.
156. Koh Y, Lim HY, Ahn JH et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2012; 23: 23.
157. van Spaendonck-Zwarts KY, Badeloe S, Oosting SF et al. Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance. Fam Cancer 2012; 11: 123-129.
158. Alrashdi I, Levine S, Paterson J et al. Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Fam Cancer 2010; 9: 239-243.
159. Gardie B, Remenieras A, Kattygnarath D et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet 2011; 48: 226-234.
160. Smit DL, Mensenkamp AR, Badeloe S et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet 2011; 79: 49-59.
161. Maxwell PH. Seeing the smoking gun: a sensitive and specific method to visualize loss of the tumour suppressor, fumarate hydratase, in human tissues. J Pathol 2011; 225: 1-3.
162. Ponti G, Pellacani G, Seidenari S et al. Cancer-associated genodermatoses: skin neoplasms as clues to hereditary tumor syndromes. Crit Rev Oncol Hematol 2012; 85: 239-256.
163. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
164. Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-1280.
165. Sudarshan S, Pinto PA, Neckers L et al. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer-a distinct form of hereditary kidney cancer. Nat Clin Pract Urol 2007; 4: 104-110.
166. Frezza C, Zheng L, Folger O et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011; 477: 225-U132.
167. Furge KA, Chen J, Koeman J et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007; 67: 3171-3176.
168. Amin MB, Paner GP, Alvarado-Cabrero I et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 2008; 32: 1822-1834.
169. Klatte T, Han KR, Said JW et al. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol 2008; 26: 604-609.
170. Mazal PR, Exner M, Haitel A et al. Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol 2005; 36: 22-28.
171. Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012; 12: 685-698.
172. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol 2010; 5: 297-348.
173. Welter C, Kovacs G, Seitz G et al. Alteration of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer 1989; 1: 79-82.
174. Gasparre G, Hervouet E, de Laplanche E et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet 2008; 17: 986-995.
175. Mayr JA, Meierhofer D, Zimmermann F et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 2008; 14: 2270-2275.
176. Menko FH, van Steensel MA, Giraud S et al. Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol 2009; 10: 1199-1206.
177. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977; 113: 1674-1677.
178. Pavlovich CP, Walther MM, Eyler RA et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002; 26: 1542-1552.
179. Souza CA, Finley R, Muller NL. Birt-Hogg-Dube syndrome: a rare cause of pulmonary cysts. AJR Am J Roentgenol 2005; 185: 1237-1239.
180. Pavlovich CP, Grubb RL 3rd, Hurley K et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 2005; 173: 1482-1486.
181. Kluijt I, de Jong D, Teertstra HJ et al. Early onset of renal cancer in a family with Birt-Hogg-Dube syndrome. Clin Genet 2009; 75: 537-543.
182. Khoo SK, Bradley M, Wong FK et al. Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene 2001; 20: 5239-5242.
183. Schmidt LS, Nickerson ML, Warren MB et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 2005; 76: 1023-1033.
184. Toro JR, Wei MH, Glenn GM et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008; 45: 321-331.
185. Warren MB, Torres-Cabala CA, Turner ML et al. Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues. Mod Pathol 2004; 17: 998-1011.
186. Nickerson ML, Warren MB, Toro JR et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2: 157-164.
187. Baba M, Hong SB, Sharma N et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 2006; 103: 15552-15557.
188. Baba M, Keller JR, Sun HW et al. The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for murine B-cell development. Blood 2012; 120: 1254-1261.
189. Furuya M, Nakatani Y. Birt-Hogg-Dube syndrome: clinicopathological features of the lung. J Clin Pathol 66: 178-86g 2012.
190. Baba M, Furihata M, Hong SB et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008; 100: 140-154.
191. Kuroda N, Tanaka A, Ohe C et al. Review of renal oncocytosis (multiple oncocytic lesions) with focus on clinical and pathobiological aspects. Histol Histopathol 2012; 27: 1407-1412.
192. Schmidt LS. Birt-Hogg-Dube syndrome: from gene discovery to molecularly targeted therapies. Fam Cancer 2012; e-pub ahead of print doi:10.1007/s10689- 012-9574-y.
193. Chen J, Futami K, Petillo D et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One 2008; 3: e3581.
194. David KA, Milowsky MI, Nanus DM. Chemotherapy for non-clear-cell renal cell carcinoma. Clin Genitourin Cancer 2006; 4: 263-268.
195. Dhillon J, Amin MB, Selbs E et al. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol 2009; 33: 44-49.
196. Wright JL, Risk MC, Hotaling J et al. Effect of collecting duct histology on renal cell cancer outcome. J Urol 2009; 182: 2595-2599.
197. Simon RA, di Sant'agnese PA, Palapattu GS et al. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid differentiation. Int J Clin Exp Pathol 2008; 1: 180-184.
198. Bex A, Larkin J, Blank C. Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities. Curr Oncol Rep 2011; 13: 240-248.
199. Oudard S, Banu E, Vieillefond A et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007; 177: 1698-1702.
200. Larkin J, Fisher R, Pickering L et al. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib. J Clin Oncol 2010; 28: e539-e540.
201. Fu L, Wang G, Shevchuk MM et al. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1alpha. Cancer Res 2011; 71: 6848-6856.
202. Kobayashi T, Minowa O, Sugitani Y et al. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci USA 2001; 98: 8762-8767.
203. Wilson C, Idziaszczyk S, Colley J et al. Induction of renal tumorigenesis with elevated levels of somatic loss of heterozygosity in Tsc1\+/-mice on a Blm-deficient background. Cancer Res 2005; 65: 10179-10182.
204. Wilson C, Idziaszczyk S, Parry L et al. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet 2005; 14: 1839-1850.
205. Kobayashi T, Minowa O, Kuno J et al. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999; 59: 1206-1211.
206. Onda H, Lueck A, Marks PW et al. Tsc2(\+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104: 687-695.
207. Hasumi Y, Baba M, Ajima R et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 2009; 106: 18722-18727.
208. Kobayashi T, Hirayama Y, Kobayashi E et al. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 1995; 9: 70-74.
209. Frew IJ, Thoma CR, Georgiev S et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008; 27: 1747-1757.
210. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006; 66: 2576-2583.
211. Bayley JP, van Minderhout I, Hogendoorn PC et al. Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma. PLoS One 2009; 4: e7987.
212. Piruat JI, Pintado CO, Ortega-Saenz P et al. The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Mol Cell Biol 2004; 24: 10933-10940.
213. Redi CA. Transgenic Mouse-Methods and Protocols, 2nd ed, vol55 Humana Press: New York, NY 2011
214. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-542.
215. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751-759.
216. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-363.
217. Killary AM, Wolf ME, Giambernardi TA et al. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 1992; 89: 10877-10881.
218. Treuting PM, Dintzis SM. Comparative Anatomy and Histology: A Mouse and Human Atlas. Academic Press: Oxford, 2012.
219. Guo G, Gui Y, Gao S et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2011; 44: 17-19.
220. Lewis A, Tomlinson I. Cancer. The utility of mouse models in post-GWAS research. Science 2012; 338: 1301-1302.
221. Ayala-Ramirez M, Chougnet CN, Habra MA et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 2012; 97: 4040-4050.
222. Malouf GG, Camparo P, Oudard S et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010; 21: 1834-1838.
223. Haase VH, Glickman JN, Socolovsky M et al. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001; 98: 1583-1588.
224. Kimura K, Iwano M, Higgins DF et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008; 295: F1023-F1029.
225. Carew JS, Esquivel JA 2nd, Espitia CM et al. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS One 2012; 7: e31120.
226. Yuen JS, Sim MY, Siml HG et al. Inhibition of angiogenic and nonangiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br J Cancer 2011; 104: 941-947.
227. Karam JA, Zhang XY, Tamboli P et al. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol 2011; 59: 619-628.
228. Schietke RE, Hackenbeck T, Tran M et al. Renal tubular HIF-2alpha expression requires VHL inactivation and causes fibrosis and cysts. PLoS ONE 2012; 7: e31034.
229. Zhou J, Brugarolas J, Parada LF. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet 2009; 18: 4428-4441.
230. Traykova-Brauch M, Schonig K, Greiner O et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med 2008; 14: 979-984.
231. Graveel C, Su Y, Koeman J et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA 2004; 101: 17198-17203.
232. Graveel CR, DeGroot JD, Sigler RE et al. Germline met mutations in mice reveal mutation-and background-associated differences in tumor profiles. PLoS One 2010; 5: e13586.
233. Hartman TR, Nicolas E, Klein-Szanto A et al. The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis. Oncogene 2009; 28: 1594-1604.
234. Alderson NL, Wang Y, Blatnik M et al. S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys 2006; 450: 1-8.